drugset
drugset / Trial / NCT00113373

Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

NCT00113373 ↗

Phase 2 Completed 28 enrolled National Cancer Institute (NCI) Gynecologic Oncology Group · collab
NaSingle-groupOpen-labelTreatment

Summary

Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well lapatinib works in treating patients with persistent or recurrent ovarian epithelial or peritoneal cancer.

Timeline

Start
2005-05
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapatinib Small molecule — Oral

Indications

malignant epithelial tumor of ovary primary peritoneal carcinoma